INGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

88.60M

+10.64%

-0.330

-19.51%

90.80M

+10.35%

-0.220

-12%

100.20M

+8.59%

-0.145

-3.33%

Estimates Revision

The market is revising Downward the revenue expectations for Inogen, Inc. (INGN) for FY2025, with the revenue forecasts being adjusted by -0.07% over the past three months. During the same period, the stock price has changed by -13.85%.

Revenue Estimates for FY2025

Revise Downward

-0.07%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.63%

In Past 3 Month

Stock Price

Go Down

-13.85%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast INGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INGN is 13.00 USD with a low forecast of 12.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

12.00

Averages

13.00

High

14.00

Current: 0.000

Low

12.00

Averages

13.00

High

14.00

B. Riley

NULL -> Buy

initiated

$14

2025-06-17

Reason

B. Riley

Price Target

$14

2025-06-17

initiated

NULL -> Buy

Reason

B. Riley initiated coverage of Inogen with a Buy rating and $14 price target.

B. Riley

Anderson Schock

Buy

initiated

$14

2025-06-17

Reason

B. Riley

Anderson Schock

Price Target

$14

2025-06-17

initiated

Buy

Reason

B. Riley analyst Anderson Schock last night initiated coverage of Inogen with a Buy rating and $14 price target. Inogen is a global leader in portable oxygen therapy, targeting chronic obstructive pulmonary disease patients, the analyst tells investors in a research note. The firm says the company's portable oxygen concentrators convert ambient air into medical-grade oxygen, allowing for greater patient mobility than traditional oxygen tanks. It believes Inogen represents a "compelling turnaround story" following a management transition in Q4 of 2023 focused on reducing friction among sales channels and on cost management strategies to drive sustainable and profitable growth. Riley views Inogen "deeply undervalued" and is encouraged by the company's turnaround momentum and five consecutive quarters of beating the Street's estimates.

Needham

Hold

Buy

upgrade

$12

2025-05-22

Reason

Needham

Price Target

$12

2025-05-22

upgrade

Hold

Buy

Reason

Needham upgraded Inogen to Buy from Hold with a $12 price target. The firm says the new management team has made "significant progress with a turnaround" which is not reflected in the share price. Inogen has returned to positive mid-single digit revenue growth, and there is potential for its growth to accelerate in the second half of 2025 and 2026, the analyst tells investors in a research note. Needham believes the company has also made progress in improving its margins, and management has taken steps to diversify into a broader respiratory device business, providing it with "several new growth drivers." It finds the stock undervalued at current levels.

Needham

Mike Matson

Hold

Reiterates

n/a

2025-04-09

Reason

Needham

Mike Matson

Price Target

n/a

2025-04-09

Reiterates

Hold

Reason

Needham

Mike Matson

Hold

Reiterates

n/a

2025-02-27

Reason

Needham

Mike Matson

Price Target

n/a

2025-02-27

Reiterates

Hold

Reason

Needham

Mike Matson

Hold

Reiterates

n/a

2025-02-26

Reason

Needham

Mike Matson

Price Target

n/a

2025-02-26

Reiterates

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Inogen Inc (INGN.O) is -8.04, compared to its 5-year average forward P/E of -758.56. For a more detailed relative valuation and DCF analysis to assess Inogen Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-758.56

Current PE

-8.04

Overvalued PE

2677.90

Undervalued PE

-4195.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

14.37

Current EV/EBITDA

18.29

Overvalued EV/EBITDA

148.45

Undervalued EV/EBITDA

-119.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.37

Current PS

0.47

Overvalued PS

2.50

Undervalued PS

0.23

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

INGN News & Events

Events Timeline

No data

News

5.0

01-07Newsfilter

Inogen Launches Aurora CPAP Masks, Expanding into Sleep Therapy Market

5.0

01-07Businesswire

Inogen Launches Aurora CPAP Masks, Expanding into Sleep Apnea Market

3.5

2025-12-19NASDAQ.COM

Three MedTech Pioneers Transforming Healthcare by 2026: AVAH, INGN, and CCLD

People Also Watch

Frequently Asked Questions

What is Inogen Inc (INGN) stock price today?

The current price of INGN is 7.03 USD — it has decreased -2.63 % in the last trading day.

What is Inogen Inc (INGN)'s business?

Inogen, Inc. is a medical technology company offering respiratory products for use in the homecare setting. It supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Its Inogen One and Inogen Rove systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen. Inogen Connect is a wireless connectivity platform for the Inogen One G4, Inogen One G5, Inogen Rove 4, and Inogen Rove 6, consisting of a front-end mobile application for use by long-term oxygen therapy users. It offers Simeox, which is an airway clearance device.

What is the price predicton of INGN Stock?

What is Inogen Inc (INGN)'s revenue for the last quarter?

Inogen Inc revenue for the last quarter amounts to 92.39M USD, increased 4.00 % YoY.

What is Inogen Inc (INGN)'s earnings per share (EPS) for the last quarter?

Inogen Inc. EPS for the last quarter amounts to -0.20 USD, decreased -20.00 % YoY.

What changes have occurred in the market's expectations for Inogen Inc (INGN)'s fundamentals?

How many employees does Inogen Inc (INGN). have?

Inogen Inc (INGN) has 766 emplpoyees as of January 10 2026.

What is Inogen Inc (INGN) market cap?

Today INGN has the market capitalization of 190.85M USD.